Abstract
Despite its monogenic nature, sickle cell disease (SCD) has a heterogenous phenotype [1] with a number of associated complications, which range in severity from mild to severe and crippling, and can affect virtually all organ systems [2]. Common SCD complications include hemolytic crisis, splenic sequestration, aplastic crisis, stroke, acute chest syndrome, osteomyelitis and vaso-occlusive crisis (VOC). While some SCD patients remain asympomatic, others may present with one or more of these complications. Several studies have evaluated potential biomarkers for SCD VOC, which can be effectively used in identifying high-risk VOC patient groups, and in the patient follow-up, but with inconsistent findings. This article discusses the predictive value of anti-annexin V autoantibodies in monitoring the onset and severity of VOC, including the nature of the pain-alleviating medication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
